eligibility_summary
Eligible: female >=18 with cervical SCC/adenosquamous/adenocarcinoma, recurrent/metastatic after 1 prior platinum doublet (+/- bev) and prior anti-PD-1/L1, RECIST-measurable, ECOG 0-1, tumor tissue available, adequate organs. Exclude: >=G2 neuropathy, severe ocular disease, IBD, CV/cerebrovascular disease, recent RT or live vaccine, other histology/active malignancy, CNS mets, active infection, Kaposi’s/Castleman’s, active HBV+HCV, severe hypersensitivity, pneumonitis/ILD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 trial in 2L recurrent/metastatic cervical cancer compares: 1) Sacituzumab tirumotecan (MK‑2870/SKB264): an antibody–drug conjugate (biologic) targeting TROP2, upon binding TROP2 on tumor cells it is internalized and releases a camptothecin/topoisomerase‑I inhibitor payload, causing DNA damage and apoptosis. 2) Treatment of physician’s choice: • Pemetrexed (antifolate antimetabolite inhibiting folate-dependent DNA synthesis). • Tisotumab vedotin (ADC to Tissue Factor [TF] delivering MMAE, a microtubule inhibitor). • Topotecan (topoisomerase‑I inhibitor). • Vinorelbine (vinca alkaloid microtubule inhibitor). • Gemcitabine (nucleoside analog inhibiting DNA synthesis). • Irinotecan (topoisomerase‑I inhibitor). Targets/pathways: MK‑2870 targets TROP2‑expressing cervical cancer cells and inhibits topo‑I, comparators inhibit DNA synthesis (antifolate/nucleoside analog), topo‑I, or microtubules, tisotumab vedotin targets TF‑expressing tumor cells.